<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899414</url>
  </required_header>
  <id_info>
    <org_study_id>DAPT for NKTCL</org_study_id>
    <nct_id>NCT04899414</nct_id>
  </id_info>
  <brief_title>Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma</brief_title>
  <official_title>Study Evaluating the Safety and Efficacy of the Dexamethasone, Azacytidine, Pegaspargase, Tislelizumab With NK/T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been&#xD;
      well-defined. This phase II study aimed to evaluate the efficacy and safety of Dexamethasone,&#xD;
      azacytidine, Pegaspargase, Tislelizumab (DAPT) regimen for patients with newly diagnosed&#xD;
      advanced stage ENKTL&#xD;
&#xD;
      , non-upper aerodigestive tract NK/T- cell lymphoma（NUAT- NKTCL）and relapsed refractory NK/T&#xD;
      cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 18, 2021</start_date>
  <completion_date type="Anticipated">October 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 18, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>1-year</time_frame>
    <description>To evaluate the overall response rate of DAPT in the treatment of NK/T cell lymphoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>NK/T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Stage III/IV or Stage I/II NUAT- NKTCL or Relapsed or Refractory NK/T- cell lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4-6 cycles of induction DAPT followed by Auto HSCT as consolidation for CR/PR fit patients ,then by PD-1 as maintenance treatment (up to 16 cycles) for received Auto-HSCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone, azacytidine, Pegaspargase, Tislelizumab</intervention_name>
    <description>Dexamethasone 40mg intravenously daily on day 1-4; azacytidine 100mg intravenously daily on day 1-5; Pegaspargase 3750 IU intravenously daily on day 1； Tislelizumab 200 mg IV on Day 1 of each 21-day as a cycle.</description>
    <arm_group_label>Stage III/IV or Stage I/II NUAT- NKTCL or Relapsed or Refractory NK/T- cell lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-70 years ,Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          -  patients with confirmed pathological diagnosis of ENKTL as defined by WHO criteria&#xD;
&#xD;
          -  at least one measurable lesion&#xD;
&#xD;
          -  hemoglobin ≥90 g/l, absolute neutrophil count ≥ 1.5 × 10^9/L, platelets ≥ 75 ×10^9/L),&#xD;
             ALT≤ 2 times upper limit of normal, serum creatinine ≤1.5 times upper limit of normal&#xD;
             （If the above indicators are abnormal but are caused by the primary disease as&#xD;
             assessed by the clinician, the treatment can be enrolled according to the clinical&#xD;
             actual situation）&#xD;
&#xD;
          -  There was no other serious disease in conflict with this program&#xD;
&#xD;
          -  Adequate respiratory function&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Adequate renal and hepatic function&#xD;
&#xD;
          -  Not pregnant or nursing ,negative pregnancy test&#xD;
&#xD;
          -  No other active malignancy requiring therapy&#xD;
&#xD;
          -  No other serious or life-threatening condition deemed unacceptable by the principal&#xD;
             investigator&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Able to understand and sign an informed consent form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NK/T cell lymphoma without confirmed pathological diagnosis;&#xD;
&#xD;
          -  Patients with early stage upper aerodigestive tract NK/T- cell lymphoma ;&#xD;
&#xD;
          -  Patients with drug allergies or metabolic disorders in the program;&#xD;
&#xD;
          -  Any uncontrolled medical diseases (including uncontrolled diabetes, severe heart,&#xD;
             lung, liver and kidney dysfunction);&#xD;
&#xD;
          -  Severe infection (excluding the following: HBsAg or anti-HBc positive patients taking&#xD;
             entecavir, tenofovir and other drugs;HCV RNA positive but taking direct anti-HCV&#xD;
             drugs);&#xD;
&#xD;
          -  Invasion of primary or secondary central nervous system tumor invasion;&#xD;
&#xD;
          -  Contradictions to chemotherapy or radiotherapy;&#xD;
&#xD;
          -  Previously other malignancy requiring therapy;&#xD;
&#xD;
          -  Peripheral nervous system disorder or mental disorder;&#xD;
&#xD;
          -  Incapacity for legal conduct, medical or ethical reasons that affect the continuation&#xD;
             of the research;&#xD;
&#xD;
          -  Other clinical investigators;&#xD;
&#xD;
          -  Combination of anti-tumor drugs outside the research program;&#xD;
&#xD;
          -  Participants evaluated inappropriate to participate in this study by principal&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Zhu, Dr.</last_name>
    <phone>+86-13910333346</phone>
    <email>zhu-jun@bjcancer.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hosptial, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yexiong Li, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University International Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaopei M Wang, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Cancer Hospital &amp; Institute</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Jun Zhu</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>DAPT</keyword>
  <keyword>Tislelizumab</keyword>
  <keyword>Non- upper aerodigestive tract NK/T- cell lymphoma</keyword>
  <keyword>R/R NK/T- cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

